Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
Open Access
- 1 June 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (6) , 701-706
- https://doi.org/10.1023/a:1008399712913
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.Journal of Clinical Oncology, 1998
- Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.Journal of Clinical Oncology, 1996
- Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancerEuropean Journal Of Cancer, 1996
- A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTCAnnals of Oncology, 1996
- S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cellsBritish Journal of Cancer, 1995
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.Journal of Clinical Oncology, 1994
- Ocular Adverse Reactions Associated with Adriamycin (Doxorubicin)American Journal of Ophthalmology, 1989